86 related articles for article (PubMed ID: 16021996)
1. [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer].
Zekanowska E; Cieśliński K; Rość D
Pneumonol Alergol Pol; 2004; 72(9-10):409-14. PubMed ID: 16021996
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
3. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
[TBL] [Abstract][Full Text] [Related]
4. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K
Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
6. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
7. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Pedersen H; Grøndahl-Hansen J; Francis D; Osterlind K; Hansen HH; Danø K; Brünner N
Cancer Res; 1994 Jan; 54(1):120-3. PubMed ID: 8261432
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
9. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Pappot H; Skov BG; Pyke C; Grøndahl-Hansen J
Lung Cancer; 1997 Jul; 17(2-3):197-209. PubMed ID: 9237155
[TBL] [Abstract][Full Text] [Related]
10. [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Leśniewska K; Wiktorowicz K
Pneumonol Alergol Pol; 2008; 76(5):321-6. PubMed ID: 19003761
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
[TBL] [Abstract][Full Text] [Related]
12. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Di Bernardo MC; Matakidou A; Eisen T; Houlston RS;
Lung Cancer; 2009 Aug; 65(2):237-41. PubMed ID: 19117638
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
16. [The prognostic value of cytokeratin 19 expression in non-small cell lung cancer].
Kosacka M; Jankowska R
Pneumonol Alergol Pol; 2007; 75(4):317-23. PubMed ID: 18080980
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
18. [The quantitative evaluation of the serum acute phase proteins (APP) of patients undergoing a curative resection for non-small cell lung cancer (NSCLC)].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Szydlik S; Leśniewska K; Krzyzanowski M
Przegl Lek; 2006; 63(10):936-40. PubMed ID: 17288188
[TBL] [Abstract][Full Text] [Related]
19. [Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer].
Zekanowska E; Cieśliński K; Kotschy M; Lambrecht W
Pneumonol Alergol Pol; 1998; 66(3-4):187-92. PubMed ID: 9857663
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]